REGULATORY

Meiji’s mRNA Vaccine, Pfizer’s RSV Vaccine Now in Line for Approval

November 28, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A fresh batch of drugs and vaccines cleared the review of a key Japanese health ministry panel on November 27, putting them in line for regulatory approval. Among them is ARCT-154, which would be the country’s first self-amplifying “replicon” mRNA…

To read the full story

Meiji’s Kostaive Booster Dose Non-Inferior to Pfizer COVID Jab: PIII Data
December 25, 2023
Meiji Set to Start Supplying COVID Jab in Japan Next Fall-Winter
November 29, 2023
Debut of Japan-Made COVID-19 Jab Is Momentous: Daiichi Sankyo President
November 29, 2023
Japan Approves Meiji’s COVID Vaccine, Daiichi Sankyo’s XBB-Tailored Jab
November 28, 2023

REGULATORY

MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026
MHLW Sets Up Drug Discovery Support Office Ahead of New Fund Launch
January 6, 2026
Ex-JPMA President Ueno Takes on New AMED Advisor Role
January 6, 2026
Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit
January 5, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…